EJHaem · 2025
Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Diebold Kendall, Parker Devan, Worth Sarah, Espinoza-Gutarra Manuel, Vachhani Pankit, Bachiashvili Kimo, Rangaraju Sravanti, Mohty Razan, Bhatia Ravi, Jamy Omer
Аннотация
BACKGROUND: Real-world evidence for hypomethylating agent (HMA) + venetoclax 50 mg (VEN50) with voriconazole and posaconazole in acute myeloid leukemia (AML), is limited.
METHODS: We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).
RESULTS: We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.
CONCLUSION: HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.
CLINICAL TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: We evaluated outcomes of patients with newly-diagnosed AML treated with HMA + VEN50 with either posaconazole (n = 23) or voriconazole (n = 95).
RESULTS: We report that treatment with HMA + VEN50 with either azole elicits a response rate similar to that described in the VIALE-A trial. Reducing the VEN dose to 50 mg with either strong CYP3A4 inhibitor did not compromise on the efficacy of the combination.
CONCLUSION: HMA + VEN50 with either posaconazole or voriconazole yields comparable responses to higher doses of VEN reported previously.
CLINICAL TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.